Indrayani Biotech Ltd Financials
Company Logo

Indrayani Biotech Ltd Financial Statement

Indrayani Biotech Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue10.40
Operating Expense8.07
Net Profit0.10
Net Profit Margin0.96
Earning Per Share0.02
EBIDTA2.34
Effective Tax Rate1.29
Invest in Indrayani Biotech Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

Indrayani Biotech Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual62.32
Operating Expenses Annual56.66
Operating Profit Annual9.28
Interest Annual4.83
Depreciation1.45
Net Profit Annual1.46
Tax Annual1.55

Indrayani Biotech Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning0.62
Cash Flow from Operations26.09
Cash Flow from Investing-7.26
Cash Flow from Financing-19.19
Cash Flow at the End0.26

Indrayani Biotech Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)15.12
PBIT Margin (%)12.79
PBT Margin (%)10.21
Net PROFIT Margin (%)2.34
Return On Networth / Equity (%)2.78
Return On Networth /Employed (%)7.23
Return On Assets (%)1.38
Total Debt / Equity (X)1
Asset Turnover Ratio (%)0.59

Indrayani Biotech Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual21.66
Total Current Assets Annual71.50
Non Current Assets Annual54.50
Total Shareholders Funds Annual54.52
Total Assets Annual126.01

Indrayani Biotech Ltd Earning Calls

EPS (INR)

Expected

0.27

Reported

0.13

Surprise

-51.85%

Jun 2024

EPS beaten by -51.85%

Mar 2024

EPS beaten by -47.37%

Dec 2023

EPS beaten by -44.23%

Get Your FAQs Right

As of Nov 23, 2024, Indrayani Biotech Ltd has a market capitalization of 223.90 Cr. Value Research classifies it as a Small-Cap company.
No, Indrayani Biotech Ltd is not debt-free with a debt-to-equity ratio of 1.16.
In FY 2023 , Indrayani Biotech Ltd recorded a total revenue of approximately 62.32 Cr marking a significant milestone in the company's financial performance.
Indrayani Biotech Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.0% annually, respectively..
Indrayani Biotech Ltd's current PE ratio is 153.36.
Indrayani Biotech Ltd's ROCE averaged 10.0% from the FY ending March 2022 to 2024, with a median of 8.4%. It peaked at 14.9% in March 2022, reflecting strong capital efficiency over the period..
Indrayani Biotech Ltd's latest EBIT is Rs. 7.84 Cr, surpassing the average EBIT of Rs. 7.27 Cr over the 5 years..